Bruno Claude Daniel Fauvet
bruno.fauvet@epfl.ch +41 21 693 38 56
+41 21 693 38 56
EPFL > SB > IPHYS > LBS
Web site: Web site: https://lbs.epfl.ch/
EXPERIENCE
Since August 2009: PhD in Prof. Hilal Lashuel's laboratory (EPFL): Use of chemical
protein synthesis to elucidate the role ?-synuclein post-translational modifications in
Health and Disease
2008-2009: Internship in Prof. Hilal Lashuel's laboratory to complete publications started during the Master project
2007-2008: Master in Life Sciences and Technology in Prof. Hilal Lashuel's
laboratory: Developing Novel Tools for Elucidating the Structure-Function
Relationship of Macrophage Migration Inhibitory Factor
Summer 2006: training course as a member of the EPFL FSV Summer Research
Program in Prof. Petersen's laboratory. Topics practiced :
- in vivo network imaging of neural activity & pharmacology
- Two-photon microscopy
Summer 2005: training course in the Laboratory of Stem Cell Dynamics (Prof. Yann
Barrandon) for 4 weeks. Topics practiced:
- Cell culture
- Immunohistochemistry
protein synthesis to elucidate the role ?-synuclein post-translational modifications in
Health and Disease
2008-2009: Internship in Prof. Hilal Lashuel's laboratory to complete publications started during the Master project
2007-2008: Master in Life Sciences and Technology in Prof. Hilal Lashuel's
laboratory: Developing Novel Tools for Elucidating the Structure-Function
Relationship of Macrophage Migration Inhibitory Factor
Summer 2006: training course as a member of the EPFL FSV Summer Research
Program in Prof. Petersen's laboratory. Topics practiced :
- in vivo network imaging of neural activity & pharmacology
- Two-photon microscopy
Summer 2005: training course in the Laboratory of Stem Cell Dynamics (Prof. Yann
Barrandon) for 4 weeks. Topics practiced:
- Cell culture
- Immunohistochemistry
EDUCATION
2008: Obtained Master degree in Life Sciences and Technology in the Laboratory of Molecular Neurobiology and Functional Neuroproteomics (Prof. Hilal Lashuel, Swiss
Federal Institute of Technology of Lausanne). Gained experience in:
- Computational structural biology
- Protein engineering
- Protein biochemistry and biophysics
2007: Preparing a Master in Life Sciences and Technology at the Swiss Federal Institute of Technology of Lausanne.
2006: Obtained a Bachelor in Life Sciences and Technology at the Swiss Federal Institute of Technology of Lausanne.
2003: obtained a French Scientific Baccalauréat with the 'Very Good' mention
Federal Institute of Technology of Lausanne). Gained experience in:
- Computational structural biology
- Protein engineering
- Protein biochemistry and biophysics
2007: Preparing a Master in Life Sciences and Technology at the Swiss Federal Institute of Technology of Lausanne.
2006: Obtained a Bachelor in Life Sciences and Technology at the Swiss Federal Institute of Technology of Lausanne.
2003: obtained a French Scientific Baccalauréat with the 'Very Good' mention
Publications
Infoscience publications
LMNN publications
The H50Q Mutation Enhances alpha-Synuclein Aggregation, Secretion, and Toxicity, in Journal Of Biological Chemistry, vol. 289, num. 32, p. 21856-21876, 2014.
. Protein semisynthesis and total synthesis approaches to elucidate the role of Alpha-Synuclein post-translational modifications. EPFL, Lausanne, 2014.
c-Abl phosphorylates ?-synuclein and regulates its degradation: implication for ?-synuclein clearance and contribution to the pathogenesis of Parkinson's disease, in Human molecular genetics, vol. 23, num. 11, p. 2858-79, 2014.
Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies, in Molecular & Cellular Proteomics, vol. 12, num. 12, p. 3543-3558, 2013.
Synthetic polyubiquitinated ?-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology, in Proceedings of the National Academy of Sciences of the United States of America, vol. 110, num. 44, p. 17726-31, 2013.
One-pot total chemical synthesis of human ?-synuclein, in Chemical communications (Cambridge, England), vol. 49, num. 81, p. 9254-6, 2013.
One-pot total chemical synthesis of human ?-synuclein, in Chemical communications (Cambridge, England), vol. 49, num. 81, p. 9254-6, 2013.
Characterization of Molecular Determinants of the Conformational Stability of Macrophage Migration Inhibitory Factor: Leucine 46 Hydrophobic Pocket, in PLoS ONE, vol. 7, num. 9, p. e45024, 2012.
Characterization of semisynthetic and naturally N?-acetylated ?-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of ?-synuclein, in The Journal of biological chemistry, vol. 287, num. 34, p. 28243-62, 2012.
?-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer, in The Journal of biological chemistry, vol. 287, num. 19, p. 15345-64, 2012.
Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: ?-synuclein phosphorylation at tyrosine 125, in Journal of the American Chemical Society, vol. 134, num. 11, p. 5196-210, 2012.
Chemical strategies for controlling protein folding and elucidating the molecular mechanisms of amyloid formation and toxicity, in Journal of molecular biology, vol. 421, num. 2-3, p. 204-36, 2012.
. Semisynthesis and Total Chemical Synthesis of alpha-synuclein to study Post-Translational Modifications in Health and Disease. 22nd American Peptide Symposium, San Diego, CA, 2011.
Phosphorylation of alpha-Synuclein at Y125 and S129 Alters Its Metal Binding Properties: Implications for Understanding the Role of alpha-Synuclein in the Pathogenesis of Parkinson's Disease and Related Disorders, in Acs Chemical Neuroscience, vol. 2, num. 11, p. 667-675, 2011.
Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action, in The Journal of biological chemistry, vol. 285, num. 34, p. 26581-98, 2010.
An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity, in Bioorganic & medicinal chemistry, vol. 18, num. 14, p. 5425-40, 2010.
A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor, in Biochemistry, vol. 48, num. 41, p. 9858-70, 2009.
. Developing Novel Tools for Elucidating the Structure-Function Relationship of Macrophage Migration Inhibitory Factor. , 2008.
. Réception par des psychiatres d'un reportage télévisuel sur la folie . , 2007.